Alterome Therapeutics presented preliminary Phase 1 data on November 20 for ALTA3263, an oral KRAS selective inhibitor designed to block many mutant forms of the protein while sparing the related HRAS and NRAS proteins. The data, from the dose escalation part of a Phase 1/1b trial, were shown in a late breaking session at the EORTC-NCI-AACR symposium in Barcelona.
In colorectal cancer, ALTA3263 combined with cetuximab shrank tumors in 5 of 16 evaluable patients, an objective response rate of 31 percent, with four responses confirmed and one unconfirmed. Disease was controlled in 15 of 16 patients, a disease control rate of 94 percent, at doses of 200 and 300 milligrams twice daily. Taken alone in pancreatic cancer, the drug produced confirmed responses in 3 of 13 evaluable patients, 23 percent, with disease control in 10 of 13, at 400 or 600 milligrams twice daily.
By the September 18 data cutoff, 120 patients had received the drug, 80 as monotherapy and 40 with cetuximab, across pancreatic, colorectal and lung cancers. Activity appeared across KRAS mutations including G12D, G12V, G12A, G13D and Q61H. Among the 80 monotherapy patients, 15 percent had treatment related side effects of grade 3 or higher; the most common effects were diarrhea, vomiting, nausea and fatigue, mostly mild to moderate.
The results are early, small and uncontrolled, and Alterome is a private company, so the commercial read is about positioning rather than valuation. Pan KRAS inhibition is one of oncology’s most contested races, and a single drug showing activity in both colorectal and pancreatic cancer, in combination and alone, gives Alterome a claim on ground that larger rivals are spending heavily to hold.